Posting of Annual Report & Notice of AGM

RNS Number : 4119Q

Hemogenyx Pharmaceuticals PLC

05 June 2018

 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

Posting of Annual Report

& Notice of Annual General Meeting

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2017 ("2017 Annual Report"), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:

https://www.hemogenyx.com/investors/annual-and-half-year-reports/default.aspx

The 2017 Annual Report will be posted to shareholders today.

The AGM is to be held on 27 June 2018 at 11am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London, EC4M 7RD.

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Sir Marc Feldmann, Executive Chairman
Optiva Securities Ltd		Tel: [phone]
Christian Dennis
Shard Capital Partners LLP		Tel: [phone]
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: [phone]
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
US Media enquiries
Lowell Goodman	Tel: [phone] or  [e-mail]

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

 

END

 

 

MSCFAMRTMBMMBIP